The New Drug Application for PARGLUVA is currently.

Bristol-Myers Squibb and Merck employees in the worldwide development and commercialization of PARGLUVA. The New Drug Application for PARGLUVA is currently. By the U.S. Food and Drug Administration If approved, PARGLUVA glitazars would the first the first marketed agent in a new class of investigational compounds. PARGLUVA is a dual alpha / gamma PPAR activator.

For more information, please contact: Media – David M. Bristol-Myers Squibb, 609-721-6155, or Tracy Ogden, Merck & Co. 484-686-4837, Investors – John Elicker, Bristol-Myers Squibb, 212-546-3775, or Graeme Bell, Merck & Co. 908-423-5185. (more…)

Page 4 of 14« First...23456...Last »

Other Posts From Category "fitness":

Related Posts